Fulcrum Therapeutics (FULC) Other Non Operating Income (2018 - 2019)
Fulcrum Therapeutics (FULC) posted quarterly Other Non Operating Income of $7000.0 for Q4 2019, little changed year-over-year from $7000.0 in Q4 2018, and little changed quarter-over-quarter from $7000.0 in Q3 2019.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Other Non Operating Income (2018 - 2019) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Other Non Operating Income for 2 consecutive years, with $7000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Other Non Operating Income changed 0.0% year-over-year to $7000.0; the TTM figure through Dec 2019 stood at $29000.0 (changed N/A YoY), while the FY2019 annual figure was $29000.0, down 92.6% from the prior year.
- Other Non Operating Income was little changed at $7000.0 in Q4 2019 per FULC's latest filing, from $7000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $8000.0 in Q2 2018 and bottomed at $7000.0 in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Fulcrum Therapeutics | 292.47 Mn | 292.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 7,000.00 |
| Sep 30, 2019 | 7,000.00 |
| Jun 30, 2019 | 8,000.00 |
| Dec 31, 2018 | 7,000.00 |
| Sep 30, 2018 | 7,000.00 |
| Jun 30, 2018 | 8,000.00 |